Accéder au contenu
Merck
  • Effect of seasonal malaria chemoprevention on the acquisition of antibodies to Plasmodium falciparum antigens in Ouelessebougou, Mali.

Effect of seasonal malaria chemoprevention on the acquisition of antibodies to Plasmodium falciparum antigens in Ouelessebougou, Mali.

Malaria journal (2017-07-20)
Almahamoudou Mahamar, Djibrilla Issiaka, Amadou Barry, Oumar Attaher, Adama B Dembele, Tiangoua Traore, Adama Sissoko, Sekouba Keita, Bacary Soumana Diarra, David L Narum, Patrick E Duffy, Alassane Dicko, Michal Fried
RÉSUMÉ

Seasonal malaria chemoprevention (SMC) is a new strategy to reduce malaria burden in young children in Sahelian countries. It consists of the administration of full treatment courses of sulfadoxine-pyrimethamine plus amodiaquine to children at monthly intervals during the malaria season. However, it is not clear if there is a cumulative effect of SMC over time on acquisition of antibodies to malaria antigens. A cross-sectional serosurvey was carried out 1 month after the last dose of SMC in 2016. Children aged 3-4 years were randomly selected from areas where SMC was given for 1, 2 or 3 years during the malaria season. Children in the areas where SMC had been implemented for 1 year but who failed to receive SMC were used as comparison group. Antibody extracted from dry blood spots was used to measure IgG levels to CSP, MSP-1 The prevalence of antibodies to AMA-1 were high and similar in children who received SMC for 1, 2 or 3 years and also when compared to those who never received SMC (96.3 vs 97.5%, adjusted OR = 0.99, 95% CI 0.33-2.97, p = 0.99). The prevalence of antibodies to MSP-1 SMC reduced seropositivity to MSP-1

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
OPD SIGMAFAST, tablet
Référence
Conditionnement
Disponibilité
Prix
Quantité